Company / SG&A Expense
Savara Inc SG&A Expense History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$25.0M
FY2024
5-year range
$10.9M / $25.0M
FY2020-FY2024
Trend
+59.8%
vs FY2023
Sector context
#192 of 213
Health Care
What the data says
Among 213 Health Care companies, Savara Inc is in the top 10% for sg&a expense. SG&A Expense has fluctuated over the past 10 years, ranging from $9M in FY2016 to $25M in FY2024.
Based on SEC 10-K filings.
$25M in FY2024 with a 5-year CAGR of +18.6%.
Increased from $11M to $25M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +26.6%
- 5-Year CAGR
- +18.6%
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 213This company $25.0M Sector average $722.3M
▼
-96.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +18.6%, indicating consistent growth.
- In FY2024, sg&a expense increased 59.8% year-over-year.
- Ranks #192 out of 213 companies in the Health Care sector.
- Lowest sg&a expense in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.86 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $25.0M | +59.8% |
| FY2023 | $15.7M | +43.4% |
| FY2022 | $10.9M | -11.5% |
| FY2021 | $12.3M | -13.4% |
| FY2020 | $14.3M | +33.9% |
| FY2019 | $10.7M | +0.0% |
| FY2018 | $10.7M | -3.9% |
| FY2017 | $11.1M | +18.6% |
| FY2016 | $9.3M | -14.8% |
| FY2015 | $11.0M | +15.5% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026